VIMTALABSNSE30 October 2023

Vimta Labs Limited has informed the Exchange about Investor Presentation

Vimta Labs Limited

Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051,Telangana, India T: +91 40 2726 4141 F +91 4027263657

Vimt

Driven by Quality. Inspired by Science.

VLL\SE\ 066\2023-24 Date: 30.10.2023

Listing Centre B S E Limited Pj Towers, Dalal Street Mumbai: 400001 Scrip Code No.524394

Dear Sirs,

Asst Vice President National Stock Exchange of India Limited Exchange Plaza”, Bandra Kurla Complex, Bandra (E) Mumbai — 400051 Trading Symbol: VIMTALABS

Reg:

Investor Presentation -Q2 results — FY 2023-24

to provisions of Regulation 30 of the SEBI

Pursuant (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) we are attaching herewith the Investor Presentation.

Further, pursuant to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., https:’/vimta.com/investor-presentationi

This is for your information and necessary records.

Yours faithfully,

for \TIMTA LABS LIMITED

Sujani Vasireddi Company Secretary

Attachments: as above.

I 4

Life Sciences Campus, #5, MN Science & Technology Park, Genome Valley, Sharnirpet, Hyderabad -500 101, Telangana, India T : +91 4067404040 F: mdoffice@vimta.com URL: wwwvimtacom CIN : L24110TG1990PLC011977

Vimta Labs Limited Investor Presentation Q2 & H1FY24

Disclaimer

The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.

Contents

Q2 & H1FY24 Earnings

Company Overview

Industry Landscape

Our Competitive Advantage

Way Forward

Q2 & H1FY24 Earnings

▪ Q2 & H1FY24 Highlights ▪ Key Metrics: Q2 & H1FY24 ▪ Profit & Loss Statement ▪ Balance Sheet ▪ Financial Track Record ▪ Shareholding Pattern

Q2 & H1FY24 Highlights

Q2FY24 Earnings Highlights

➢ Total Income for Q2FY24 was at Rs. 754 Mn a de-growth of 6.4% YoY

➢ EBITDA for Q2FY24 was Rs. 179 Mn a decline of 31.4% YoY; EBITDA margin was at 23.8%

➢ Q2FY24 PAT was at Rs. 63 Mn a decline of 52.1% YoY

➢ Basic EPS in Q2FY24 was Rs. 2.9

H1FY24 Earnings Highlights

➢ Total Income for H1FY24 was at Rs. 1,595 Mn a de-growth of 0.7% YoY

➢ EBITDA for H1FY24 was Rs. 432 Mn a decline of 15.3% YoY; EBITDA margins at 27.1%

➢ H1FY24 PAT was at Rs. 185 Mn a decline of 26.6% YoY

➢ Basic EPS was Rs. 8.4 in H1FY24 against Rs. 11.4 in H1FY23

➢ Cash and Cash equivalents at Rs. 262 Mn as of 30th September 2023

➢ Cash flow From Operations at Rs. 268 Mn for H1FY24; H1FY24 Capex at Rs. 421 Mn

➢ Debt to Equity ratio 0.07

Key Metrics: Q2 & H1FY24

Q2FY24 SNAPSHOT

Total Income1 (In ₹ Mn)

EBIDTA & EBIDTA Margin1 (In ₹ Mn, %)

PAT & PAT Margin1 (In ₹ Mn, %)

Basic EPS (In ₹)

806

841

754

6.4% YoY

250

225

200

175

150

125

100

32%

30%

24%

261

252

179

31.4% YoY

16%

15%

132

122

18%

16%

14%

12%

10%

150

125

100

52.1% YoY

6.0

5.5

2.9

Q2FY23 Q1FY24 Q2FY24

Q2FY23

Q1FY24

Q2FY24

EBIDTA

EBIDTA Margin

PAT

PAT Margin

H1FY24 SNAPSHOT

Total Income1 (In ₹ Mn)

EBIDTA & EBIDTA Margin1 (In ₹ Mn, %)

PAT & PAT Margin1 (In ₹ Mn, %)

Basic EPS (In ₹)

1,606

1,595

H1FY23

H1FY24

0.7% YoY

525 500 475 450 425 400 375 350 325 300 275 250 225 200 175 150 125 100 75 50 25 -

32%

27%

509

432

H1FY23

H1FY24

33%

32%

31%

30%

29%

28%

27%

26%

25%

15.3% YoY

270

220

170

120

-3 0

16%

252

12%

185

H1FY23

H1FY24

26.6% YoY

EBIDTA

EBIDTA Margin

PAT

PAT Margin

11.4

H1FY23

8.4

H1FY24

Profit & Loss Statement

Particulars (₹ Mn)

Revenue from Operations

Other Income

Total Income

Material and Testing Costs

Cost of lab setup

Changes in inventories of work-in-progress

Employee benefits expense

Other expenses

Total Expenses

EBIDTA

EBIDTA (%)

Finance costs

Depreciation expense

Profit before tax

PBT (%)

Tax

Profit for the year

PAT (%)

Basic EPS (INR)

Q2 FY24

Q2 FY23

YoY (%)

Q1 FY24

QoQ(%)

H1 FY24

H1 FY23

YoY (%)

734

754

182

253

139

575

179

799

806

166

233

144

545

261

23.8%

32.4%

11.1%

8.4%

2.9

178

22.0%

132

16.4%

-8.1%

-6.4%

5.6%

-31.4%

-52.8%

-52.1%

835

841

204

247

136

588

252

30.0%

163

19.4%

122

14.5%

-12.1%

1,569

1,590

-1.3%

-10.3%

1,595

1,606

-0.7%

386

356

-2.2%

-29.0%

-48.5%

-48.1%

500

275

1164

432

27.1%

174

247

460

276

1097

509

31.7%

148

344

15.5%

21.4%

185

11.6%

8.4

252

15.7%

11.4

6.1%

-15.3%

-28.1%

-26.6%

-26.8%

6.0

-52.2%

5.5

-48.2%

Balance Sheet

Particulars (₹ Mn)

Assets Fixed Assets Capital work-in-progress Goodwill Intangible assets Other non-current assets Total non current assets Trade Receivable Inventories Cash and cash equivalents including Bank Balance Other current asset Total current assets Total Assets Equity Total Equity Liabilities Non-current liabilities (i)Long-term Borrowings (ii) Other non current liabilities Total non current liabilities Current liabilities (i)Short-term Borrowings including current maturities (ii) Trade Payables (iii) Other current liabilities Total current liabilities Total Equity and Liabilities

30 September 2023 (Unaudited)

31 March 2023 (Audited)

31 March 2022 (Audited)

1,641 270 56 107 147 2,221 830 245 262 215 1,552 3,773

2,967

74 154 228

119 94 364 577 3,773

1,570 123 56 122 116 1,987 800 226 398 213 1,637 3,623

2,818

99 134 233

51 144 377 573 3,623

1,498 3 56 134 138 1,828 769 174 114 186 1,244 3,072

2,340

127 128 255

67 123 287 477 3,072

Financial Track Record

TOTAL INCOME (₹ Mn)

PROFITABILITY (₹ Mn)

EBITDA & EBITDA Margin

18%

25%

29%

31%

PAT & PAT Margin

15%

1,837

2,115

2,797

3,216

20.5% CAGR

330

538

817

984

44.0% CAGR

10%

214

413

482

91.6% CAGR

FY20

FY21

FY22

FY23

FY20

FY21

FY22

FY23

FY20

FY21

FY22

FY23

Total Revenue

EBIDTA

EBIDTA Margin

PAT

PAT Margin

BALANCE SHEET RATIOS

RoE (%)

RoCE (%)

Debt to Equity

Total Capex

11%

18%

17%

15%

18%

25%

22%

FY20

FY21

FY22

FY23

FY20

FY21

FY22

FY23

0.16

0.08

0.05

FY20

FY21

FY22

FY23

166

357

450

492

FY20

FY21

FY22

FY23

Shareholding Pattern

Shareholding as on 30th September 2023

Share Information as on 30th September 2023

Others 58.8%

NSE Ticker

BSE Ticker

Market Cap (INR Cr)

% free-float

Promoters 37.0%

Free-float market cap (INR Cr)

Total Debt (INR Mn)

Cash & Cash Equivalents (INR Mn)

Shares Outstanding

3M ADTV (Shares)*

3M ADTV (INR Cr)*

Industry

*Source: NSE & BSE #Cash and Cash equivalents includes other bank balances

DII 1.5%

FII 2.7%

VIMTALABS

524394

1,274

62.8%

802

193

262

2,21,47,347

129,611

6.72

TIC

Company Overview

▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation

Vimta Labs at a Glance

Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing.

39+ Years

Of experience in CRTO industry

400,000+

Sq.ft. of Ultra modern lab space

3,216

FY23 Total Revenue (In ₹ Mn)

Our Belief & Commitment

1,400+

75+

Dedicated Multi Disciplinary Team

Successful Regulatory Audits

Regional & Satellite labs across India

In India: ➢ Pharma Analytical & Preclinical

Services

➢ Food Testing Services

984

FY23 EBIDTA (In ₹ Mn)

482

FY23 PAT (In ₹ Mn)

30.6%

EBIDTA MARGIN

15.0%

PAT MARGIN

14.9% YoY

20.3% YoY

16.6% YoY

Our Journey

Infrastructure

People

Investment

Capabilities

Revenues

2023

400,000+ ft2

1400+

492 M

2015

400,000+ ft2

1000+

580 M

2006

200,000+ ft2

600+

992 M

1992

50,000+ ft2

150+

85 M

Pharma & Biopharma: Discovery & development services; Food; Environment; Clinical Diagnostics; Electronics

Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment

Clinical Research; Environment; Analytical – Food & Pharma

Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research

3,216 M

1,073 M

542 M

16 M

1984

500 ft2

200,000

Minerals & ores; Metals; Rice bran oil testing

156,000

• •

Investment & Revenues in INR Investments depicted may have spread across more than the denoted year

Our Offerings (1/3)

Drug discovery and development support to Lifesciences Industry

Offerings

Industry

Accreditations & Regulatory Approvals

Food & Agriculture Services

Electronics & Electricals Testing

Clinical Diagnostics

Environment Testing & Consultancy

Pharma Analytical

Clinical Research

Preclinical Support

Pharmaceuticals

DCGI, USFDA, WHO, NPRA, UK MHRA and other European countries

Services

➢ Leader in India for a wide range of

➢ One of India’s most reputed and

analytical services for the pharmaceutical, biopharmaceutical and animal health industries.

➢ E&L studies ➢ Stability testing ➢ Method development ➢ Validations ➢ Genotoxic impurities ➢ Elemental analysis ➢ In vitro studies

➢ Physical

characterization ➢ Dissolution testing ➢ Microbiology ➢ Immunogenicity ➢ Characterization ➢ Bioassays

reliable CROs

➢ Experience of over 2,000 clinical

studies

➢ Impressive track record of

successful global regulatory audits from national and international regulatory authorities.

Pharmaceuticals, Biotech, Medical device, Agrochemicals

Good Laboratory Practices (GLP) - certified by NGCMA, and AAALAC accredited

➢ General and Genetic toxicology ➢ Safety pharmacology ➢ Development and Reproductive

Toxicology (DART) studies

➢ Immunotoxicology ➢ Comprehensive pharmacological and

drug metabolism and pharmacokinetic studies

➢ Wide gamut of Toxicology services also support agrochemical and medical device industries

Our Offerings (2/3)

Drug discovery and development support to Lifesciences Industry

Offerings

No. of Laboratories

Accreditations & Regulatory Approvals

Services

Food & Agriculture Services

Electronics & Electricals Testing

Clinical Diagnostics

Environment Testing & Consultancy

Food Testing

Electronics & Electricals Testing

FSSAI, NABL, BIS, APEDA, EIC, Spices Board

ISO 17025 accredited by NABL and approved by TEC

➢ VIMTA is a ‘National Referral Lab’ and a preferred

➢ Newly launched EMI / EMC services cater to IT,

laboratory partner for many MNCs, and also relied on by Government institutes for projects of national importance

automotive, aviation & defence, medical devices, telecom, home appliance / consumer electronics and allied industries

➢ Routine as well as specialized testing services for food and agriculture products to assist with R&D, regulatory compliance, trade and internal quality requirements

➢ Support new product development, and offer

multifarious analytical services for: ➢ The feed that sustains animal life ➢ Crops yielded by various soils ➢ All varieties of food and food products for consumption/export ➢ Milk, water and beverages ➢ Nutraceuticals

➢ Services provided are EMI / EMC TESTING, Radiated, Conducted, Environmental testing, Mechanical & electrical safety testing, Performance testing, Product certification

➢ The non EMI / EMC services are rendered through our wholly owned subsidiary, Emtac Laboratories Pvt. Ltd

Our Offerings (3/3)

Drug discovery and development support to Lifesciences Industry

Food & Agriculture Services

Electronics & Electricals Testing

Clinical Diagnostics

Environment Testing & Consultancy

Offerings

Clinical Diagnostics

Environment Testing & Consultancy

No. of Laboratories

2 (regional reference laboratories); 6 (branch laboratories)

Accreditations & Regulatory Approvals

Services

ISO 15189 by NABL, CAP

MoEF, ISO 17025 by NABL, QCI/NABET, OSHAS 45000

➢ Strong brand equity and a pan India presence offering

➢ Environment Impact Assessments and Environment

both routine and specialized diagnostic services

➢ The hallmarks of our clinical diagnostics services are stringent quality systems, latest technologies and committed customer care ➢ Clinical diagnostics range:

➢ Biochemistry ➢ Haematology ➢ Molecular biology ➢ Microbiology ➢ Histopathology / Cytopathology ➢ Serology ➢ Cytogenetics

Testing since inception. Provide our services to various industries such as power, infrastructure, steel, cement, oil & gas, mining, pharmaceutical, food, chemical etc.

➢ Our Services:

➢ Testing of water, waste water,

air, soil, noise

➢ Post-project monitoring,

environment compliance studies ➢ EIA & social impact assessments ➢ Deep-ocean studies, marine

ecological studies

➢ Forestry and ecological studies ➢ Rejuvenation & clean-up

consultancy

➢ Ground water studies & contamination studies

➢ Site due diligence, remediation

strategies

➢ Social sustainability, climate change and environmental education projects ➢ Mining plan preparation ➢ EHS audits ➢ Work space monitoring etc. ➢ Green Audit

Geographical Presence

Headquartered in Hyderabad, VIMTA has 19 laboratories across India, with a total laboratory space of over 400,000 sq. ft.

Hyderabad (Headquarters)

Food

Clinical Diagnostics

Pharma

Electronics & Electrical

Environment

Food

Ahmedabad

Noida

Mumbai (NFL)

Pune

Bengaluru

Nellore

Kolkata

Environment

Clinical Diagnostics

Chennai

Noida

Kolkata

Chennai

Delhi

Varanasi

Kolkata

Bhubaneswar

Visakhapatnam

Vijayawada

Tirupati

Key Management Team

S P Vasireddi Executive Chairman

Harita Vasireddi Managing Director

Sreenivas Neerukonda Executive Director

Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.

Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.

Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.

Her Core competencies include management & driving organizational adaptabilty and development, quality management systems, and risk management.

She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India

Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal oriented performance.

He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.

Key Management Team (Cont’d)

Harriman Vungal Executive Director - Operations

Suresh Kumar President

Narahari Naidu D.R. Chief Financial Officer

Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.

He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.

He holds D. Tech in Electronics from Toronto, Canada.

Suresh have more than two decades of experience in Testing, Inspection, Certification and Contract Research Organization with diversified products and industries.

He was with TUV SUD South Asia as Chief Operating Officer and Member of Board of Management before Joining VIMTA

He holds B.Sc (Tech) from ICT Mumbai and B.Sc (Polymer Chemistry) from Kerala university .

Narahari has close to 15 years of experience in diversified industries.

His core competencies include Financial Planning, Corporate Strategy, Fund raising, Banking & Treasury, Taxation, Investor Relations, Enterprise Risk Management, Compliance & Governance, Financial Reporting & Audit, Procurement Strategies.

He is a Chartered Accountant (CA) and a Company Secretary (CS).

Industry Landscape

▪ Market Opportunity ▪ Factors Driving Industry Growth

Markets Opportunity

Preclinical

Food Testing

Clinical Testing

Environment Testing

Electronics Testing

Pharmaceutical & Biopharmaceuticals

957.6

405.5

a b o G

76.6

127.3

19.5

40.5

76.2

124.7

11.1

20.2

6.8

13.4

2020 | 2028 CAGR: 11.3%

2023 | 2028 CAGR: 10.7%

2022 | 2032 CAGR: 7.5%

2022 | 2028 CAGR: 8.5%

2022 | 2030 CAGR: 7.8%

2021 | 2031 CAGR: 7.1%

) n b D S U (

n a d n

130.0

42.0

43.6

14.5

0.5

1.0

0.6

0.9

0.2

0.4

0.05

0.1

2021 | 2030

CAGR: 13.4%

2021 | 2030

CAGR: 7.5%

2022 | 2027

CAGR: 9.3%

2022 | 2032

CAGR: 11.6%

2021 | 2026

CAGR: 9.9%

2021 | 2028

CAGR: 8.6%

Factors Driving Industry Growth

Drug Discovery & Development

Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry

Specialized knowledge, skills and testing tools that CROs can provide

Food Testing

Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third- party inspection & testing

Electrical & Electronics Testing

Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives

Green push by Government for electrical vehicles

Environment Testing

Diagnostics

Increase in regulations to address the growing concerns of air, water and soil contamination

Health risks from communicable diseases, life style diseases, growing population and urbanization is driving the demand for precise diagnostic testing

Growing demand in wellness segment

Our Competitive Advantage

▪ Our Position in the CRTO Landscape ▪ Our Strength

Our Position in the CRTO Landscape

Pharma Analytical & Preclinical

Food Testing

#1 in India

Customers – 90% of India top 20

Customers – 70% of India top 10

30% revenues from overseas

Clinical Research

Environment

Among the most reputed CROs in India

Among top 5 in India

80% of revenues from overseas

Customers – PSUs, large corporations across industries

Clinical Diagnostics

Electronics & Electricals

Among leading labs in TS, AP, UP states

Start-up

Our Strengths

QUALITY Long & successful regulatory track record – cGMP, GLP, GCP

CUSTOMER CENTRICITY Long term partnerships with customers

INFRASTRUCTURE Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium

KNOWLEDGE

Multi-disciplinary, knowledgeable, skilled and trained manpower

TECHNOLOGY Wide range of current technologies with expandable capacities

Way Forward

▪ Our Key Growth Drivers & Strategies

Our Key Growth Drivers & Strategies

Favourable markets

Core business strategies

Core operational strategies

Best practices

✓ Growth momentum

✓ Capacity expansions

✓ Operational excellence

in markets

✓ Growing demand for safe & quality - drugs, food, diagnostics, electronics & clean environment

✓ Service innovations

✓ Hiring right talent

✓ Penetration into new

✓ Quality & compliance

markets

✓ Customer partnerships

culture

✓ Cutting edge technologies

✓ Good corporate governance

✓ Risk management

✓ Listening to customers’

needs

✓ Continuous learning

We aspire to reach revenues of >Rs.500 cr by 2025/2026

Thank You

October 2023

VIMTA LABS LIMITED

INVESTOR RELATIONS AT

Registered Office Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051

NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Website: www.Vimta.com

Vimta Labs Ltd. Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com

Rahul Thakur Rahul.Thakur@in.ey.com

Advait Bhadekar Advait.Bhadekar@in.ey.com

← All Transcripts VIMTALABS Stock Page →

Vimta Labs Limited has informed the Exchange about Investor Presentation

Market Movers